Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy

Phase 2

Completed

Conditions: Recurrent Childhood Anaplastic Astrocytoma
Recurrent Childhood Cerebellar Astrocytoma
Childhood High-grade Cerebral Astrocytoma
Recurrent Childhood Anaplastic Oligoastrocytoma
Childhood High-grade Cerebellar Astrocytoma
Recurrent Childhood Anaplastic Oligodendroglioma
Recurrent Childhood Cerebral Astrocytoma
Recurrent Childhood Brain Tumor
Recurrent Childhood Glioblastoma
Recurrent Childhood Visual Pathway and Hypothalamic Glioma

Interventions: Drug: cilengitide
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2008-05-16

Last Posted Date: 2018-08-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00679354

Locations: 🇺🇸
Kaiser Permanente-Oakland, Oakland, California, United States
🇺🇸
University of California San Francisco Medical Center-Parnassus, San Francisco, California, United States
🇺🇸
Lombardi Comprehensive Cancer Center at Georgetown University, Washington, District of Columbia, United States

and more 17 locations

Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer

Phase 1

Completed

Conditions: Malignant Neoplasm

Interventions: Drug: Cixutumumab
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Temsirolimus

First Posted Date: 2008-05-16

Last Posted Date: 2015-11-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 72

Registration Number: NCT00678769

Locations: 🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Bowman-Birk Inhibitor Concentrate in Healthy Men

Phase 1

Completed

Conditions: Healthy, no Evidence of Disease

Interventions: Drug: Bowman-Birk inhibitor concentrate
Other: placebo
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2008-05-16

Last Posted Date: 2016-12-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 20

Registration Number: NCT00679094

Locations: 🇺🇸
Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States

AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers

Phase 1

Completed

Conditions: Neoplasms

First Posted Date: 2008-05-15

Last Posted Date: 2018-07-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 23

Registration Number: NCT00678132

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function

Phase 1

Completed

Conditions: Neoplasms
Lymphoma

First Posted Date: 2008-05-07

Last Posted Date: 2019-11-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 8

Registration Number: NCT00674024

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Cognitive Effects of Bariatric Surgery

Completed

Conditions: Bariatric Surgery Patients

First Posted Date: 2008-05-05

Last Posted Date: 2018-03-07

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 253

Registration Number: NCT00671775

Locations: 🇺🇸
Columbia, New York, New York, United States

Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer

Phase 2

Terminated

Conditions: Metastatic Renal Cell Cancer
Metastatic Cancer
Metastatic Melanoma

Interventions: Biological: Anti-NY ESO-1 T-cell receptor PBL
Drug: aldesleukin
Drug: Cyclophosphamide
Drug: fludarabine phosphate
Biological: ALVAC NY ESO-1 vaccine

First Posted Date: 2008-05-02

Last Posted Date: 2019-11-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 45

Registration Number: NCT00670748

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery

Phase 1

Active, not recruiting

Conditions: Pancreatic Acinar Cell Carcinoma
Locally Advanced Pancreatic Adenocarcinoma
Pancreatic Ductal Adenocarcinoma
Stage III Pancreatic Cancer AJCC v6 and v7
Stage IV Pancreatic Cancer AJCC v6 and v7

Interventions: Biological: Falimarev
Biological: Inalimarev
Other: Laboratory Biomarker Analysis
Biological: Sargramostim

First Posted Date: 2008-04-30

Last Posted Date: 2025-04-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT00669734

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Phase 2

Completed

Conditions: Recurrent Melanoma
Stage IIA Melanoma
Stage IIB Melanoma
Stage IIC Melanoma
Stage IV Melanoma

Interventions: Drug: saracatinib

First Posted Date: 2008-04-29

Last Posted Date: 2014-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 23

Registration Number: NCT00669019

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors

Phase 2

Completed

Conditions: Glioblastoma
Gliosarcoma
Anaplastic Astrocytoma
Anaplastic Oligodendroglioma
Anaplastic Mixed Oligoastrocytoma

Interventions: Biological: Bevacizumab
Drug: MLN-518 (Tandutinib)
Procedure: Quality-of-life assessment

First Posted Date: 2008-04-28

Last Posted Date: 2015-11-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 42

Registration Number: NCT00667394

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy